Sonoma Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on a special meeting of stockholders held by Sonoma Pharmaceuticals, Inc. on May 30, 2019. The company is incorporated in Delaware and its common stock (SNOA) and warrants (SNOAW) trade on The NASDAQ Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
Stockholders voted on a proposal to amend the Restated Certificate of Incorporation to authorize a reverse stock split at a ratio between 1-for-6 and 1-for-9. The results were as follows:
- Total shares entitled to vote: 11,972,328
- Shares present or represented by proxy: 6,422,382
- Percentage of returned votes in favor: 72%
- Percentage of outstanding shares voting in favor: 38.5%
Because the proposal required approval by a majority of outstanding shares, the measure failed. Consequently, the Special Meeting was adjourned to June 11, 2019, to allow additional time for shareholders to vote.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on operations, or specific risk factors beyond the immediate need to secure shareholder approval for the reverse stock split to maintain compliance or market status.
Key Facts for Investor Verification
- Verify the outcome of the adjourned special meeting scheduled for June 11, 2019.
- Confirm whether the Board of Directors proceeds with the reverse stock split if the proposal passes at the adjourned meeting.
- Monitor the company's compliance with NASDAQ listing requirements regarding stock price and share count.